Key Collaborations and Vaccine Launches are Anticipated to Drive the Global Recombinant Vaccine Market

The global recombinant vaccine market is anticipated to grow at a CAGR of 3.36% during the forecast period. The key companies operating in the industry are highly inclined towards the adoption of different growth strategies including capacity expansion, partnerships, mergers, and acquisitions, geographical expansions, and product innovations to remain competitive in the market. For instance, in July  2020, Sanofi and GlaxoSmithKline have collaborated with the U.S Government to supply 100 million doses of their COVID-19 recombinant protein-based vaccine. This collaboration aimed to meet the government’s  Operation Warp Speed Goal, to ensure the availability of 100 million effective covid-19 vaccine doses in a rapid manner. Moreover, the companies also collaborated with the UK government to supply up to 60 million doses of recombinant protein-based COVID-19 vaccine. Further, the companies also announced the collaboration with global health organizations, businesses, and leaders of governments  to speed up the production activities and ensure equitable access to COVID-19 treatments and vaccines 

Browse the full report description “Global Recombinant Vaccine Market Size, Share & Trends Report by Type (Sunbit Vaccine and Live Attenuated Vaccine), By Route of Administration (Oral and Parenteral), by Disease (Human Papilloma Virus, Hepatitis b, Rotavirus, and Others), and by Distribution channel (Hospitals and Retail Pharmacies and Government Suppliers) Forecast (2022-2028)” at https://www.omrglobal.com/industry-reports/recombinant-vaccines-market 

Additionally, in May 2021, Bavarian Nordic A/S has partnered with Dynavax Technologies Corp with an intent to commercialize and distribute the Heplisav-b. Heplisav –b is a recombinant hepatitis b vaccine developed by Dynavax Technologies Corp. In February 2021, the European Commission granted the marketing authorization for Heplisav-b for immunization against hepatitis –b virus infection in individuals of 18 years and above. Furthermore, in  November 2021, The Phillippine Food and Drug Administration granted an emergency use authorization of recombinant nanoparticle protein-based COVID-19 with Matrix-M adjuvant. The vaccine will be manufactured in the Philippines by the Serum Institute of India (SII) under the brand name COVOVAX. Thus, product launches and key collaborations are anticipated to accelerate the growth of the global recombinant vaccine market during the forecast period.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028

Segment Covered- 

• By Type 
• By Route of Administration
• By Disease
• By Distribution Channel 

Regions Covered-

• North America
• Europe
• Asia-Pacific
• Rest of the World

Competitive Landscape-  GlaxoSmithKline plc, Sanofi S.A., and Novartis International AG, among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected regions and segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Recombinant Vaccine  Market Report Segment

By Type 

• Sunbit Vaccine
• Live Attenuated  

By Route of Administration

• Oral 
• Parenteral

By Disease 

• Human Papilloma Virus
• Hepatitis b
• Rotavirus
• Others

By Distribution Channel 

• Hospital and Retail Pharmacies 
• Government Supplier

Global Recombinant Vaccine  Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe 

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific 

Rest of the World

• Latin America 
• Middle East & Africa

To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/recombinant-vaccines-market